NCT06826066 Involvement of the Immune System in Intrinsic Radiosensitivity
| NCT ID | NCT06826066 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-05-12 |
| Primary Completion | 2027-05-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-05-12 with a primary completion date of 2027-05-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Radiotherapy is one of the major treatments for cancer. It may be indicated in more than two-thirds of patients, regardless of cancer location or disease stage. The mechanisms of radiotherapy action are numerous: halting tumor proliferation, inducing tumor cell death, triggering anti-tumor immune responses, and ensuring both local and systemic tumor control. As a result, current treatments are highly effective, providing, for instance, a 5-year overall survival rate of about 90%-95% for localized breast and prostate cancers.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Patients who have been treated with radiotherapy * Absence of toxicity grade 2 or higher * Patients without psychiatric, sociological, family, or geographical difficulties that could interfere with patient compliance to the protocol or follow-up * Information and signed informed consent * Affiliated with social security Exclusion Criteria: * Inability to obtain patient consent * Patient refusing blood sample collection * Patient deprived of liberty or under legal protection (under guardianship, under curatorship) * Patients who have experienced radiation-induced toxicity of grade 2 or higher * Disease progression, relapse * Patient under State Medical Aid
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06826066 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06826066 currently recruiting?
Yes, NCT06826066 is actively recruiting participants. Contact the research team at yazid.belkacemi@aphp.fr for enrollment information.
Where is the NCT06826066 trial being conducted?
This trial is being conducted at Créteil, France.
Who is sponsoring the NCT06826066 clinical trial?
NCT06826066 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 40 participants.